Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Cadrenal Therapeutics, a leading biopharmaceutical company, is making waves in the medical field with its groundbreaking development, tecarfarin. This late-stage novel oral and reversible anticoagulant, also known as a blood thinner, is designed to prevent heart attacks, strokes, and deaths caused by blood clots in patients with certain rare medical conditions. The company recently announced its participation in the highly anticipated Lytham Partners Fall 2023 Investor Conference, where Cadrenal Therapeutics’ CEO, Quang Pham, will be taking part in a Company Webcast and Panel Presentation.

The Company’s webcast presentation is scheduled to be available for viewing on Tuesday, October 17, 2023, at 7:00 am ET. Interested individuals can access the webcast on Cadrenal Therapeutics’ official website or through this link: [ or]. For those unable to catch the live webcast, an archived version will be made available for replay.

In addition to the webcast, Quang Pham will be participating in a panel discussion titled “Cardiac Kids: Late-Stage Advancement for Cardiovascular Disorders.” This virtual panel, scheduled for Tuesday, October 17, 2023, at 10:30 am ET, promises to shed light on the exciting advancements in the field of cardiovascular medicine. To join the panel, interested individuals can visit: [].

Furthermore, Cadrenal Therapeutics’ management will be conducting one-on-one meetings with investors throughout the event. These virtual meetings provide an excellent opportunity for investors to gain deeper insights into the company’s innovative pipeline and future prospects. To arrange a meeting with Cadrenal Therapeutics’ management, interested parties can reach out to Lytham Partners at 1× or register through this link: [].

Cadrenal Therapeutics is at the forefront of developing tecarfarin, a revolutionary anticoagulant that has garnered orphan drug and Fast Track designations for its potential to prevent systemic thromboembolism in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Unlike the commonly prescribed Vitamin K Antagonist, warfarin, tecarfarin leverages a different metabolism pathway, making it a promising alternative for preventing thrombosis. The drug has undergone extensive evaluation in eleven human clinical trials involving over 1,000 individuals. Results from Phase 1, Phase 2, and Phase 2/3 trials have shown that tecarfarin is generally well-tolerated by both healthy adults and patients with chronic kidney disease.

Cadrenal Therapeutics’ dedication to developing innovative solutions for rare medical conditions is commendable. With tecarfarin’s potential to revolutionize anticoagulant therapy, the company is poised to make a significant impact on the lives of patients at risk of heart attacks, strokes, and blood clots. For more information about Cadrenal Therapeutics and its groundbreaking work, please visit their official website at [].

For any further inquiries, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
Phone: 858-337-0766

Lytham Partners, LLC
Robert Blum, Managing Partner
Phone: 602-889-9700

Cadrenal Therapeutics’ participation in the Lytham Partners Fall 2023 Investor Conference is a testament to the company’s commitment to advancing medical breakthroughs and improving patient outcomes. This event provides a platform for Cadrenal Therapeutics to showcase its innovative tecarfarin and engage with investors who share their vision for a healthier future.

Leave a comment